Advertisement
Screener

Vor Biopharma Inc. (VOR) Material Contracts

Vor Biopharma Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-08-11: Form 10-Q; Exhibit 10.2; Description Registration Rights Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein.
  • 2026-08-11: Form 10-Q; Exhibit 10.1; Description Securities Purchase Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein.
  • 2026-06-12: Form 8-K; Exhibit 10.1; Description Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan..
  • 2026-05-13: Form 10-Q; Exhibit 10.2; Description Registration Rights Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein.
FiledFormExhibitDescription
2026-08-1110-Q10.2Registration Rights Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein
2026-08-1110-Q10.1Securities Purchase Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein
2026-06-128-K10.1Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan.
2026-05-1310-Q10.2Registration Rights Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein
2026-05-1310-Q10.1Securities Purchase Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein
2026-03-3010-K10.15Non-Employee Director Compensation Policy
2026-03-278-K10.2Form of Registration Rights Agreement.
2026-03-278-K10.1Form of Securities Purchase Agreement.
2026-01-028-K10.1Separation Agreement, dated as of December 31, 2025, by and between the Company and Qing Zuraw.
2025-12-188-K10.2Form of Registration Rights Agreement.
2025-12-188-K10.1Form of Securities Purchase Agreement.
2025-11-1310-Q10.6Amendment to Employment Agreement, dated November 2, 2025, by and between the Registrant and Qing Zuraw
2025-08-278-K10.1Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan
2025-08-1210-Q10.10BOSTON, MA OFFICE LEASE AGREEMENT
2025-08-1210-Q10.9License Agreement, dated as of June 25, 2025, by and between RemeGen Co, Ltd. and the Registrant
2025-07-228-K10.1Employment Agreement, dated as of July 17, 2025, by and between the Company and Qing Zuraw
2025-07-108-K10.1Employment Agreement, dated as of July 9, 2025, by and between the Company and Sandesh Mahatme.
2025-06-268-K10.7Employment Agreement, dated as of June 25, 2025, by and between the Company and Jean-Paul Kress.
2025-06-268-K10.6Transition Agreement, dated as of June 25, 2025, by and between the Company and Robert Ang.
2025-06-268-K10.5Form of Support Agreement, dated June 25, 2025, by and between the Company and the stockholders named therein.
2025-06-268-K10.4Form of Registration Rights Agreement, dated June 25, 2025, by and between the Company and the investors named therein.
2025-06-268-K10.3Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Company and the investors named therein.
2025-06-268-K10.2Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Company and Yantai Rongpu Investment Partnership (Limited Partnership).
2025-06-268-K10.1Form of Pre-Funded Warrant to Purchase Common Stock.
2025-03-2010-K10.17Offer Letter, by and between the Registrant and Eyal Attar, dated October 4, 2022
2024-12-278-K10.2Form of Registration Rights Agreement.
2024-12-278-K10.1Form of Securities Purchase Agreement.
2024-11-0710-Q10.1Offer Letter, by and between the Registrant and Han Choi, dated September 19, 2024
2024-05-288-K10.1Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan.
2023-05-1110-Q10.1Non-Employee Director Compensation Policy
2022-12-078-K10.1Securities Purchase Agreement, dated as of December 7, 2022, by and between Vor Biopharma Inc. and RA Capital Healthcare Fund, L.P.
2022-08-1110-Q10.1Separation Agreement, by and between the Registrant and Christopher Slapak, dated May 11, 2022
2021-11-1010-Q10.1Second Amendment to Exclusive License Agreement, by and between the Registrant and The Trustees of Columbia University in the City of New York, dated November 8, 2021
2021-06-178-K10.2Second Amendment to Lease, by and between the Company and the Landlord, dated June 15, 2021.
2021-06-178-K10.1First Amendment to Lease, by and between the Company and PPF Off 100 Cambridge Park Drive, LLC (“Landlord”), dated June 15, 2021.

Similar stocks

Stock NameCountryMarket CapPE Ratio
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10